J&J, AstraZeneca explore modifying Covid vaccines in response to rare blood clot issue – CNBC

ORLANDO, FLORIDA, UNITED STATES – 2021/04/10: Johnson & & Johnson COVID-19 vial and box seen at a vaccination website.
Getty ImagesJohnson & & Johnson and AstraZeneca are carrying out early stage research into whether possible modifications of their Covid-19 vaccines could reduce or get rid of the threat of rare, but severe, blood clots associated with the shots.The blood clotting issue, which some researchers are calling vaccine-induced immune thrombotic thrombocytopenia, or VITT, has been connected to both shots. Researchers have actually been discovering ideas into how the embolisms form, improving hopes of potentially reengineering the shots, a person familiar with the matter informed CNBC.The Wall Street Journal reported the news earlier Tuesday.In a declaration to CNBC, J&J stated it supports “continued research study and analysis as we deal with medical professionals and global health authorities.””Johnson & & Johnson stays committed to assisting end this lethal pandemic as rapidly as possible, and we continue to believe in the favorable benefit-risk profile of our vaccine,” the company said.AstraZeneca said it is “actively dealing with the regulators and clinical community to comprehend these very uncommon blood-clotting occasions, consisting of information to drive early diagnosis and intervention, and appropriate treatment.”The Food and Drug Administration said in April it was adding a warning label to J&Js Covid vaccine, citing the blood-clotting disorder as an uncommon side effect.On Monday, the FDA said it was adding yet another cautioning to J&Js label, keeping in mind the shot has actually been linked to a major, however unusual, autoimmune disorder called Guillain-Barre syndrome.About 100 preliminary reports of Guillain-Barre have been detected after 12.8 million dosages of the J&J vaccine were administered, according to the Centers for Disease Control and Prevention. The cases reported after getting the J&J shot mainly happened about two weeks after vaccination and primarily in males, many aged 50 years and older, CDC data shows. The readily available information does not reveal a similar pattern with Pfizers or Modernas vaccine, the agency said.The FDA and CDC on April 13 asked states to temporarily halt using J&Js vaccine “out of an abundance of care” while it investigated six women, ages 18 to 48, who developed cerebral venous sinus apoplexy, or CVST, in combination with low blood platelets within about 2 weeks of receiving the shot.They suggested resuming use of the shot 10 days later on after the CDC figured out that the advantages of the inoculations exceeded their risks.The Journals report Tuesday noted that modification of the vaccines may need changes to ownership rights or regulatory approvals.

Leave a Reply

Your email address will not be published. Required fields are marked *